ANZCTR search results

This prospective single centre outcome study will document in a longitudinal manner the clinical outcome of high tibial osteotomy. Patients who undergo a High Tibial Osteotomy by Dr Leo Pinczewski between 2000 and 2002 will be invited to participate. At 5 and 10 years after their surgery patients will be contacted by the researchers and invited to return for clinical assessment.

A 2-Part, Single-Dose Study to Evaluate the Interaction of Etoricoxib and Tizanidine MR when Co-administered or Administered Alone in Healthy Subjects MK0663B (combination treatment) is being developed for the treatment of acute pain in musculoskeletal conditions with swelling and muscle spasm. However, this study is in healthy volunteers only.

This study examines survivorship and the clinical outcome in a series of 340 consecutive patients 10 years after TKR with the Genesis II prosthesis. All arthroplasties were performed by a single surgeon over a 3 year period.

Injury to the ACL is a well-recognized risk factor for post-traumatic knee osteoarthritis (OA). Degenerative radiographic changes are evident in 50-70% of people 10-15 years after the injury. In such cases, surgical reconstruction does not typically improve OA prognosis. Since knee OA has the potential to have a substantial negative impact on an individual, affecting their quality of life, physical function, and work status, it is important that this subgroup of individuals be investigated. It is well established that knee biomechanics, including joint motions and loads, are altered following ACL injury, and are not restored with surgical reconstruction. These biomechanical changes are frequently reported as a cause of cartilage damage and subsequent post-traumatic knee OA, due to changes in joint contact pressures and load distribution. Therefore, the focus of this program of research will be directed towards an intervention that may restore more normal knee joint biomechanics. The targeted brace (Donjoy unloader brace) has the potential to enhance knee joint function. It is primarily designed to control abnormal sagittal and transverse plane movements associated with ACL reconstruction, in addition to correcting frontal plane malalignment, which is a common feature of knee OA. The brace is targeted to an individual by compartmental distribution of OA (medial or lateral tibiofemoral, TFJ) and frontal plane knee alignment (varus or valgus). The brace can adjusted in the frontal plane to offload either medial or lateral TFJ compartment for use in medial and lateral TFJ OA, respectively. The degree of frontal plane adjustment is based on individual’s comfort during walking. However, no study to date has evaluated the capacity of knee bracing to restore knee joint function in individuals with knee OA following ACL reconstruction. The aims of this study are to evaluate, in individuals with knee OA after ACL reconstruction: i) the immediate effects of the targeted brace on lower limb biomechanics; ii) the short-term (4-week) effects of the targeted brace on pain, confidence and physical function; and iii) the medium-term (4-month) effects of the brace on pain, function and quality of life. Given that the knee brace has the potential to reduce knee pain and enhance physical function in arthritic patients, it is hypothesized that the immediate effects of the brace will be to improve knee joint kinematics, reduce external joint moments (associated with ACLR), reduce pain, as well as improve confidence, physical function and quality of life in these patients. The findings of this study will reveal whether knee biomechanics in people who have developed knee OA after ACL reconstruction can be altered by the targeted knee brace. It will also reveal whether the targeted brace can reduce pain, improve confidence, function and quality of life. If the brace can modulate the abnormal biomechanics in the reconstructed knee, it may slow OA progression and may be used to prevent the development of OA following ACLR, thus reducing the associated personal and societal costs of this common and debilitating condition.

This study will assess if a safe non-invasive transcutantous electrical stimulation can treat chronic constipation from the anorectal retention sub-group (the most common type of chronic constipation). Hypothesis TESIC can increase large bowel motility and defecation to overcome chronic constipation in children with AR, and is more effective than current best treatment (CBT, laxatives, diet, toilet timing and posture, education about brain-gut axis) alone.

To determine whether: (i) A protein preload stimulates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) secretion, and thereby reduces postprandial glycaemia following a carbohydrate-containing meal relative to a control condition. (ii) Galvus (vildagliptin) enhances the effect of a protein preload to stimulate GLP-1 and GIP secretion, and thereby further reduces postprandial glycaemia following a carbohydrate-containing meal.

The purpose of this physiology study is to examine the effects of common sleeping pills (sedatives) on the awakening (arousal) response to respiratory stimuli during sleep and their effects on upper airway muscles, airway function, and breathing responses during sleep.

Obesity is becoming pandemic in the Australian population. Successful attempts to lose weight and maintain weight loss are dependent on regular physical activity. This training study will establish if high-intensity intermittent exercise will induce fat loss in overweight men. The current wisdom is that one should exercise at relatively low intensity because at this level fat is the dominant substrate used as a fuel. We are proposing that there is still significant fat utilization at higher exercise intensities and exercising at this higher intensity will lead to greater fat loss over time, as well as greater gains in health related fitness parameters. The opportunity to achieve greater benefits from a reduced time commitment may act as an inducement for reluctant exercisers to commence a fitness program. To our knowledge, the effects of training at higher intensities on regional and total fat deposits of overweight men has not been measured before. Pre- and posttraining testing will include body composition measures of anthropometry, bioimpedance, DEXA, CT, and vascular assessment. We hypothesize that 12 weeks of interval sprinting will result in significant fat loss and significant increase in aerobic fitness. Sixty subjects will be recruited and randomly assigned to one of two groups: Group 1 (n=30) interval training with work:rest ratio of 8 s: 12 s and Group 2 (n=30) a non-exercising control group. Testing protocols will also include a VO2max cycle ergometer test that will allow determination of maximum oxygen carrying capacity. Blood sampling will be used to determine blood lactate, fasting glucose, catecholamines, insulin, adiponectin, leptin and glycerol concentrations. Subjects will be given food diaries to complete to ensure that total energy intake, as well as macronutrient balance, is maintained over the study period. Subjects will also perform three tasks (see below) before and after the intervention so that vascular response can be assessed. Subjects will also be asked to complete a food intake diary in which they record the quantity and type of food they eat during each day. Random days will be selected for this purpose. Tasks The Stroop task involves verbally responding to coloured words displayed every second on a computer (5 minutes). An isometric handgrip task will involve subjects contracting a handgrip dynamomanometer at 30% of their maximal voluntary contraction for 5 min. Blood flow will be measured in the non-exercising arm. The leg cycle exercise task will involve subjects cycling at a low-moderate level of their maximal oxygen uptake (40%) on a stationary ergometer 8 minutes). Blood flow will also be assessed in the non-exercising arm. Each subject will be involved in a familiarity session involving exposure to the different tasks.

The purpose of this study is to investigate whether the early use of a blood clotting drug during peritonectomy surgery reduces the amount of bleeding that occurs and so reduces the amount of blood transfusion you may need. Who is it for? You may be eligible to join this study if you are aged 18 years or above and are scheduled to undergo a peritonectomy. Trial details: Peritonectomy surgery is associated with a high risk of bleeding and many patients will require what is known as massive blood transfusion. This typically involves a transfusion of at least 10 units of blood or roughly your whole blood volume. In this research we hope to compare two treatments. Half the participants will receive the standard treatment used in this hospital. This involves the use of blood clotting factors and blood transfusion. In addition patients who have persistently high blood loss are sometimes given a treatment called recombinant factor VIIa. The other half of the participants will receive a product known as Prothrombinex-VF early in the operation when the anaesthetist suspects that there will be high blood loss. Prothrombinex-VF is a commercial product that contains blood clotting factors – these help the blood clot. All other treatment will be the same as usual practice. With this research we hope to be able to show that early use of Prothrombinex-VF reduces the need for blood transfusion and the overall need for blood products such as blood clotting factor preparations.

Paliperidone palmitate (Invega Sustenna) is a recently approved long acting injectable antipsychotic medication to treat schizophrenia that is only required to be administered monthly, unlike others which require daily or fortnightly administration. It is useful in people where previous drugs have been ineffective, or where taking oral medications has been a problem as doses are more closely monitored and clinical staff will know quickly when doses are missed. For Invega Sustenna to be approved for use in adults by the government, a number of studies were conducted in adults aged 18-65 that showed it was effective, and that its benefits outweighed any side effects. It is assumed that this information will be applicable to an elderly population with schizophrenia, but this has not been directly studied. In this study we will explore how effective the medication is as well as its safety and how well tolerated Invega Sustenna is in an elderly population with schizophrenia where a clinical decision has been made to commence treatment using the drug. The study will add a number of measures to standard care to measure whether the symptoms of schizophrenia are changed and also whether there are any significant side effects. After ensuring that all participants meet our inclusion and exclusion criteria, we will conduct frequent assessments of patients over a 6 month period. This information will be used to treat any side effects as soon as they occur and to build up a profile of the side effects that could be expected to be seen in the elderly and add to the knowledge about the side effects of this medication in an elderly population. The results will be published in a medical journal and provided to the drug company so that they can update their product information so that any side effects can be better dealt with.